{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:53:16Z","timestamp":1774713196912,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jaclp.2020.12.009","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T18:38:17Z","timestamp":1610649497000},"page":"404-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The Use of \u03b2-Adrenergic Receptor Antagonists in Psychiatry: A Review"],"prefix":"10.1016","volume":"62","author":[{"given":"Tyler G.","family":"Boyce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina T.","family":"Ballone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M.","family":"Certa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaclp.2020.12.009_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.pharmthera.2006.11.006","article-title":"Adrenergic pharmacology and cognition: focus on the prefrontal cortex","volume":"113","author":"Ramos","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaclp.2020.12.009_bib2","first-page":"32","article-title":"\u03b2-Blockers: a systematic review","volume":"3","author":"Kumar","year":"2011","journal-title":"J\u00a0Chem"},{"key":"10.1016\/j.jaclp.2020.12.009_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-2002-20585","article-title":"Calcium and beta receptor antagonist overdose: a review and update of pharmacological principles and management","volume":"23","author":"Newton","year":"2002","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jaclp.2020.12.009_bib4","doi-asserted-by":"crossref","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","article-title":"PubChem 2019 update: improved access to chemical data","volume":"47","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaclp.2020.12.009_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.56808\/3027-7922.2443","article-title":"Beta-blocker and its neuropsychiatric effects","volume":"44","author":"Lertvipapath","year":"2020","journal-title":"Thai J Pharm Sci"},{"key":"10.1016\/j.jaclp.2020.12.009_bib6","series-title":"A\u00a0Guide to Treatments That Work. Fourth","first-page":"463","article-title":"Pharmacological treatments for panic disorer, generalized anxiety disorder, specific phobia, and social anxiety disorder","author":"Kimmel","year":"2015"},{"key":"10.1016\/j.jaclp.2020.12.009_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(73)93190-5","article-title":"Electrocardiogram, plasma catecholamines and lipids, and their modification by oxyprenolol when speaking before an audience","volume":"2","author":"Taggart","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jaclp.2020.12.009_bib8","first-page":"CD001206","article-title":"Pharmacotherapy for social anxiety disorder (SAnD)","volume":"10","author":"Williams","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 12","key":"10.1016\/j.jaclp.2020.12.009_bib9","first-page":"20","article-title":"Pharmacotherapy of social anxiety disorder: what does the evidence tell us?","volume":"67","author":"Davidson","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.25149\/1756-8358.1102013","article-title":"Treating anxiety with either beta blockers or Antiemetic Antimuscarinic drugs: a review","volume":"11","author":"Dooley","year":"2015","journal-title":"Ment Health Fam Med"},{"issue":"4 Pt 2","key":"10.1016\/j.jaclp.2020.12.009_bib11","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/0002-8703(84)90599-4","article-title":"Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo","volume":"108","author":"James","year":"1984","journal-title":"Am Heart J"},{"key":"10.1016\/j.jaclp.2020.12.009_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00006842-198211000-00008","article-title":"Stage fright in musicians: a model illustrating the effect of beta blockers","volume":"44","author":"Neftel","year":"1982","journal-title":"Psychosom Med"},{"key":"10.1016\/j.jaclp.2020.12.009_bib13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/0269881108097716","article-title":"The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures","volume":"24","author":"Papadopoulos","year":"2010","journal-title":"J\u00a0Psychopharmacol (Oxford)"},{"key":"10.1016\/j.jaclp.2020.12.009_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/10401239809148813","article-title":"Betaxolol in anxiety disorders","volume":"10","author":"Swartz","year":"1998","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00004714-199112000-00003","article-title":"A\u00a0controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients","volume":"11","author":"Ravaris","year":"1991","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2020.12.009_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00004714-200010000-00011","article-title":"Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial","volume":"20","author":"Hirschmann","year":"2000","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2020.12.009_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for\u00a0the treatment of anxiety disorders: systematic review and\u00a0meta-analysis","volume":"30","author":"Steenen","year":"2016","journal-title":"J\u00a0Psychopharmacol (Oxford)"},{"issue":"suppl 4","key":"10.1016\/j.jaclp.2020.12.009_bib18","first-page":"23","article-title":"The pharmacotherapy of panic disorder","volume":"66","author":"Pollack","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib19","first-page":"e1","article-title":"Treatment of generalized anxiety disorder","volume":"13","author":"Huh","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.jaclp.2020.12.009_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-0327(87)90017-6","article-title":"Beta-blockers in anxiety disorders","volume":"13","author":"Hayes","year":"1987","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.jaclp.2020.12.009_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/026988119000400106","article-title":"Effects of selective beta-adrenoceptor blockade on anxiety associated with flight phobia","volume":"4","author":"Ekeberg","year":"1990","journal-title":"J\u00a0Psychopharmacol (Oxford)"},{"key":"10.1016\/j.jaclp.2020.12.009_bib22","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1177\/00220345910700091401","article-title":"Effect of a beta-adrenergic blocking agent on dental anxiety","volume":"70","author":"Liu","year":"1991","journal-title":"J\u00a0Dent Res"},{"key":"10.1016\/j.jaclp.2020.12.009_bib23","series-title":"Anxiety Disorders: A Guide for Integrating Psychopharmacology and Psychotherapy","first-page":"240","article-title":"Specific phobia","author":"Shearer","year":"2013"},{"key":"10.1016\/j.jaclp.2020.12.009_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/070674378402900705","article-title":"The effects of timolol maleate on subjective and physiological components of air travel phobia","volume":"29","author":"Campos","year":"1984","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.janxdis.2018.05.001","article-title":"Enhancement of exposure therapy in participants with specific phobia: a randomized controlled trial comparing yohimbine, propranolol and placebo","volume":"57","author":"Meyerbr\u00f6ker","year":"2018","journal-title":"J\u00a0Anxiety Disord"},{"key":"10.1016\/j.jaclp.2020.12.009_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.288.3.351","article-title":"Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction","volume":"288","author":"Ko","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaclp.2020.12.009_bib27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41371-020-0303-y","article-title":"The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study","volume":"34","author":"Agustini","year":"2020","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.jaclp.2020.12.009_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2015.11.018","article-title":"Initiation of \u03b2-blocker therapy and depression after\u00a0acute myocardial infarction","volume":"174","author":"Ranchord","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jaclp.2020.12.009_bib29","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00268-017-3935-5","article-title":"Does beta-blockade Reduce the risk of depression in patients with Isolated severe Extracranial injuries?","volume":"41","author":"Ahl","year":"2017","journal-title":"World J Surg"},{"key":"10.1016\/j.jaclp.2020.12.009_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/hup.2465","article-title":"Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis","volume":"30","author":"Liu","year":"2015","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jaclp.2020.12.009_bib31","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.120.15605","article-title":"Antihypertensive drugs and risk of depression: a Nationwide population-based study","volume":"76","author":"Kessing","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jaclp.2020.12.009_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-0028-1094624","article-title":"Action of propranolol in mania: comparison of effects of the d- and the l-stereoisomer","volume":"12","author":"Emrich","year":"1979","journal-title":"Pharmakopsychiatr Neuropsychopharmakol"},{"key":"10.1016\/j.jaclp.2020.12.009_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/13651500050518064","article-title":"Pharmacotherapy of mania: a review","volume":"4","author":"Segal","year":"2000","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.jaclp.2020.12.009_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.psychres.2014.09.005","article-title":"Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies","volume":"225","author":"Wood","year":"2015","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jaclp.2020.12.009_bib35","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1017\/S0033291709992376","article-title":"Human amygdala reactivity is diminished by the \u03b2-noradrenergic antagonist propranolol","volume":"40","author":"Hurlemann","year":"2010","journal-title":"Psychol Med"},{"key":"10.1016\/j.jaclp.2020.12.009_bib36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.neuroscience.2004.08.018","article-title":"Disruption of reconsolidation but\u00a0not\u00a0consolidation of auditory fear conditioning by noradrenergic blockade in the amygdala","volume":"129","author":"Debiec","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.jaclp.2020.12.009_bib37","first-page":"CD006239","article-title":"Pharmacological interventions for preventing post-traumatic stress disorder (PTSD)","author":"Amos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaclp.2020.12.009_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2215-0366(14)00121-7","article-title":"Pharmacological prevention of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis","volume":"2","author":"Sijbrandij","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1755-5949.2010.00227.x","article-title":"Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery","volume":"18","author":"Hoge","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.jaclp.2020.12.009_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11920-015-0582-0","article-title":"Augmentation of evidence-based psychotherapy for PTSD with Cognitive Enhancers","volume":"17","author":"Marin","year":"2015","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jaclp.2020.12.009_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1176\/appi.ajp.2017.17050481","article-title":"Reduction of PTSD symptoms with Pre-reactivation propranolol therapy: a randomized controlled trial","volume":"175","author":"Brunet","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1192\/bjp.bp.109.070540","article-title":"Acute antipsychotic-induced akathisia revisited","volume":"196","author":"Poyurovsky","year":"2010","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/0706743718760288","article-title":"The Assessment and treatment of antipsychotic-induced akathisia","volume":"63","author":"Pringsheim","year":"2018","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0006-3223(90)90540-I","article-title":"Metoprolol versus propranolol","volume":"27","author":"Adler","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib45","first-page":"255","article-title":"A\u00a0placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia","volume":"52","author":"Wells","year":"1991","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib46","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/schbul\/sbq089","article-title":"Beta-blocker supplementation of standard drug treatment for schizophrenia","volume":"36","author":"Shek","year":"2010","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaclp.2020.12.009_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004850-200103000-00006","article-title":"Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study","volume":"16","author":"Caspi","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2020.12.009_bib48","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4088\/JCP.v57n1003","article-title":"Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients","volume":"57","author":"Allan","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jaclp.2020.12.009_bib49","first-page":"CD003299","article-title":"Pharmacological management for agitation and aggression in people with acquired brain injury","author":"Fleminger","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaclp.2020.12.009_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.rehab.2015.11.001","article-title":"Care management of the agitation or aggressiveness crisis in patients with TBI. Systematic review of the literature and practice recommendations","volume":"59","author":"Luaut\u00e9","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"key":"10.1016\/j.jaclp.2020.12.009_bib51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02699052.2017.1419377","article-title":"Pharmacological management of agitation among individuals with moderate to severe acquired brain injury: a systematic review","volume":"32","author":"Mehta","year":"2018","journal-title":"Brain Inj"},{"key":"10.1016\/j.jaclp.2020.12.009_bib52","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1016\/j.ridd.2013.08.015","article-title":"Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: a systematic review","volume":"34","author":"Ward","year":"2013","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.jaclp.2020.12.009_bib53","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.ijcard.2013.05.068","article-title":"Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information","volume":"168","author":"Barron","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaclp.2020.12.009_bib54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.1997.03550010054039","article-title":"Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas","volume":"278","author":"Shorr","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jaclp.2020.12.009_bib55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-017-0781-0","article-title":"Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study","volume":"15","author":"Morales","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jaclp.2020.12.009_bib56","first-page":"CD002992","article-title":"Cardioselective beta-blockers for reversible airway disease","volume":"4","author":"Salpeter","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaclp.2020.12.009_bib57","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaclp.2020.12.009_bib58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.9740\/mhc.n197904","article-title":"An overview of clinically significant drug interactions between medications used to treat psychiatric and medical conditions","volume":"4","author":"Hoeft","year":"2014","journal-title":"Ment Health Clinician"},{"key":"10.1016\/j.jaclp.2020.12.009_bib59","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11920-012-0284-9","article-title":"Clinically significant psychotropic drug-drug interactions in the primary care setting","volume":"14","author":"English","year":"2012","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jaclp.2020.12.009_bib60","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2165\/11591710-000000000-00000","article-title":"Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management","volume":"25","author":"Gugger","year":"2011","journal-title":"CNS Drugs"}],"container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296020300124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296020300124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:41:39Z","timestamp":1757407299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667296020300124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2667296020300124"],"URL":"https:\/\/doi.org\/10.1016\/j.jaclp.2020.12.009","relation":{},"ISSN":["2667-2960"],"issn-type":[{"value":"2667-2960","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of \u03b2-Adrenergic Receptor Antagonists in Psychiatry: A Review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Academy of Consultation-Liaison Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaclp.2020.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}